
Angiogenic marker assessment, such as the ratio of soluble fms‐like tyrosine kinase 1 (sFlt‐1) to placental growth factor (PlGF), is a useful tool in predicting pre‐eclampsia. However, evidence on surveillance strategies in pregnancies with pre‐eclampsia diagnosis is lacking. Therefore, this study aimed to assess the predictive performance of longitudinal maternal serum angiogenic marker assessment for adverse maternal and perinatal outcomes compared to standard laboratory parameters in pregnancies with confirmed pre‐eclampsia. Longitudinal maternal serum angiogenic marker assessment is a good predictor of adverse maternal and perinatal outcomes and superior to some of the conventional laboratory parameters in pregnancies with pre‐eclampsia. More studies should focus on optimal surveillance following the diagnosis of pre‐eclampsia.
Like
Save
Share